In Brief: GDUFA inspections, FDA’s inspection workforce, device warning letters, 3D drug printers, CMC/GMP guidance agenda
This article was originally published in The Gold Sheet
FDA discusses GDUFA II inspectional transparency issues with industry; FDA plans global workforce; device warning letter rate fell; why FDA needs a 3D drug printer; and CMC trumps GMP in FDA agenda.
You may also be interested in...
Sponsors say transparency is important as generic drug user fee negotiations move to inspection policy.
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.